Lunaphore’s first product reaches the market

Share this article

Lunaphore has acquired the CE marking for its product and will be commercializing it across Europe as of today.

“Lunaphore’s tumor analysis system LabSatTM detects and classifies tumors more quickly and reliably than existing solutions. The microfluidic system, developed through doctoral research at EPFL, is designed for use by research labs, pharmaceutical companies and hospitals. It hits the market today.”

12.03.2019

12.03.2019

07.03.2019

BioAlps is supported by the Cantons of Bern, Fribourg, Vaud, Neuchâtel, Geneva, Valais and Jura, by the Swiss State Secretariat for Economics Affairs (SECO), and by all key research institutions in the region